Medical prevention of cardiovascular disease in general practice: Is medical treatment appropriate to global risk?;Medikamentöse prävention von kardiovaskulären erkrankungen: Verschreiben hausärzte risikoangemessen?

Zeitschrift fur Allgemeinmedizin

Volumn 83, Issue 9, 2007, Pages 359-364

  Keller, Heidemarie ^a   Krones, T ^a   Sonnichsen A ^b   Sadowski, E ^a   Popert, U ^c   Rochon, J ^d   Kaufmann Kolle, P ^e   Szecsenyi, J ^e   Baum, E ^a   Donner Banzhoff, N ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b PARACELSUS MEDICAL UNIVERSITY   (Austria)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

^d UNIVERSITY OF REGENSBURG   (Germany)

^e AQUA Institut Göttingen   (Germany)

Author keywords

Appropriateness; Cardiovascular risk; General practice; Medical treatment

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; GENERAL PRACTICE; HIGH RISK POPULATION; HUMAN; PRESCRIPTION; RISK ASSESSMENT; RISK FACTOR; SECONDARY PREVENTION;

EID: 35148842630     PISSN: 09376801     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-985833     Document Type: Article

References (25)

1. McGrae M, McDermott M. The International Pandemic of Chronic Cardiovascular Disease. JAMA 2007; 297: 1253-1254
2. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular. Munster (PROCAM) study Circulation 2002; 105 (3): 310-315
3. Third Joint Task Force of European other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2003; 24: 1601-1610
4. Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24 (11): 987-1003
5. D'Agostino RB, Russell MW, Huse DM, et al. Primary and subsequent coronary risk appraisal: new results from the Framigham study. Am Heart J 2000; 139: 272-281
6. Alderman MH. Blood Presssure Management: Individualized Treatment Based on Absolute Risk and the Potential for Benefit. Ann Int Med 1993; 119: 329-335
7. Jackson R. Guidelines on preventing cardiovascular disease in clinical practice. BMJ 2000; 320: 659-661
8. Donner-Banzhoff N. EBM in der Allgemeinmedizin. In: Kunz R, Raspe HH, Jonitz G, et al. (Hrsg). Lehrbuch Evidenzbasierte Medizin in Klinik und Praxis. Köln: Deutscher Ärzteverlag 2000; 198-204
9. British Cardiac Society, British Hyperlipidaemia Association, British Hypertenstion Society British Diabetic Association Joint British recommendations on prevention of coronary heart disease in clinical practice: summary. BMJ 2000; 320: 705-708
10. Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation 1991; 83 (1): 356-362
11. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97 (18): 1837-1847
12. Sullivan LM, Massaro JM, D'Agostino Jr RB. Presentation of multivariate data for clinical use: The Framingham Study risk score functions. Stat Med 2004; 23 (10): 1631-1660
13. Sadowski EM, Eimer C, Keller H, et al. Evaluation komplexer Interventionen: Implementierung von ARRIBA-Herz, einer Beratungsstrategie für die Herz-Kreislaufprävention. Z Allg Med 2005; 81: 429-434
14. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-33
15. LaRosa JC, He j, Vupputuri S. Effect of Statins on Risk of Coronary Heart Disease. JAMA 1999; 282: 2340-2346
16. Anti-thrombotic Trialists' Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. BMJ 2002; 324: 71-86
17. Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. JAMA 1993; 270: 1589-1589
18. Donner-Banzhoff N, Keller H, Sadowski EM, et al. Individualisierte Risikoprognose für die Herz-Kreislauf-Prävention: ein Werkstattbericht. In: Kunz R, Ollenschläger G, Raspe H, Jonitz G, Donner-Banzhoff N. (Hrsg). Lehrbuch Evidenzbasierte Medizin in Klinik und Praxis. Köln: Dt. Ärzteverlag 2007; 295-304
19. Sönnichsen AC, Rambeck M, Donner-Banzhoff N, Baum E. Cholesterin-bestimmung beim "Check ab 35": Hat die Untersuchung Konsequenzen? Z Allg Med 2006; 82: 431-434
20. Völler H, Klein G, Gohlke H, et al. Sekundärprä vention Koronarkranker nach stationärer Rehabilitation. Dtsch med Wochenschr 2000; 125: 1457-1461
21. Armstrong D, Reyburn H, Jones R. A study of general practioners' reasons for changing their prescribing behaviour. BMJ 1996; 12: 949-952
22. Britten N, Stevenson FA, Barry CA, et al. Misunderstandings in prescribe decisions in general practice: qualitative study. BMJ 2000; 320: 484-488
23. Stevenson FA, Greenfield SM, Jones M, et al. GPs' perceptions of patient influence on prescribing. Family Practice 1999; 16: 255-261
24. Simon D, Schorr G, Wirtz M, et al. Development and first validation of the Shared decision-making Questionnaire (SDM-Q). In Patient Education and Counselling 2006; 63 (3): 319-327
25. Krones T, Keller H, Sönnichsen AC, et al. Partizipative Entscheidungsfindung in der kardiovaskulären Risikoprävention: Ergebnisse der Pilotstudie von ARRIBA-Herz, einer konsultationsbezogenen Entscheidungshilfe für die allgemeinmedizinische Praxis. Z Med Psychol 2006; 15: 61-70